CAJ | 학술논문

目的：观察及比较不同剂量米非司酮在子宫腺肌病中的临床应用价值。方法选取2012年2月~2013年10月于本院采用米非司酮治疗的62例子宫腺肌病患者为研究对象，将患者根据米非司酮的应用剂量分为A组(6.25 mg/d)31例和B组(12.50 mg/d)31例，然后将两组患者治疗前后的子宫大小、痛经程度、血清CA125水平及阳性率、不良反应发生率进行分别统计及比较。结果两组治疗后1、3、6个月的子宫大小、痛经程度、血清CA125水平及阳性率比较，差异无统计学意义(P均>0.05)，两组的上述指标与治疗前比较，差异有统计学意义(P均<0.05)；A组的不良反应发生率明显低于B组(P<0.05)。结论6.25 mg/d的米非司酮在子宫腺肌病中的临床应用价值更高，具有较佳的治疗效果及更高的安全性。
목적：관찰급비교불동제량미비사동재자궁선기병중적림상응용개치。방법선취2012년2월~2013년10월우본원채용미비사동치료적62례자궁선기병환자위연구대상，장환자근거미비사동적응용제량분위A조(6.25 mg/d)31례화B조(12.50 mg/d)31례，연후장량조환자치료전후적자궁대소、통경정도、혈청CA125수평급양성솔、불량반응발생솔진행분별통계급비교。결과량조치료후1、3、6개월적자궁대소、통경정도、혈청CA125수평급양성솔비교，차이무통계학의의(P균>0.05)，량조적상술지표여치료전비교，차이유통계학의의(P균<0.05)；A조적불량반응발생솔명현저우B조(P<0.05)。결론6.25 mg/d적미비사동재자궁선기병중적림상응용개치경고，구유교가적치료효과급경고적안전성。
Objective To observe and compare the clinical application value of different dose of mifepristone in ade-nomyosis. Methods 62 patients with adenomyosis in our hospital from February 2012 to October 2013 were selected as the study objects,and they were divided into the group A (6.25 mg/d,n=31) and the group B (12.50 mg/d,n=31) accord-ing to the application dose of mifepristone,then the uterine size,dysmenorrhea degree,serum CA125 level and positive rate of CA125 before and after treatment and adverse reaction rate of the two groups were respectively analyzed and compared. Results There was no statistical difference of uterine size,dysmenorrhea degree and serum CA125 level and positive rate of CA125 after 1 month,3 and 6 months treatment in the two groups (all P>0.05),and there was a statistical difference of above-mentioned indicators after treatment in the two groups compared with before treatment (all P<0.05). The incidence rate of adverse reaction in the group A was obviously lower than that in the control group (P<0.05). Conclusion The clinical application value of 6.25 mg/d mifepristone in the treatment of adenomyosis is higher,and it has good treatment effect and the higher safety.